[go: up one dir, main page]

MX2012003220A - Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido. - Google Patents

Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.

Info

Publication number
MX2012003220A
MX2012003220A MX2012003220A MX2012003220A MX2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A MX 2012003220 A MX2012003220 A MX 2012003220A
Authority
MX
Mexico
Prior art keywords
cis
pharmaceutical formulations
lipid vehicle
retinyl esters
retinyl
Prior art date
Application number
MX2012003220A
Other languages
English (en)
Inventor
Ronald Erwin Boch
Original Assignee
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadra Logic Tech Inc filed Critical Quadra Logic Tech Inc
Publication of MX2012003220A publication Critical patent/MX2012003220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

Se describen formulaciones farmacéuticas que comprenden 9-cis-retinil ésteres en un vehículo de lípido como terapias de reemplazo de retinoide para tratar degeneraciones retinales en seres humanos.
MX2012003220A 2009-09-15 2009-09-30 Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido. MX2012003220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24274109P 2009-09-15 2009-09-15
PCT/US2009/059126 WO2011034551A2 (en) 2009-09-15 2009-09-30 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle

Publications (1)

Publication Number Publication Date
MX2012003220A true MX2012003220A (es) 2012-08-03

Family

ID=43242391

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003220A MX2012003220A (es) 2009-09-15 2009-09-30 Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.

Country Status (12)

Country Link
US (3) US20120178806A1 (es)
JP (2) JP5663025B2 (es)
KR (1) KR101710505B1 (es)
CN (1) CN102612375B (es)
AR (1) AR076184A1 (es)
AU (1) AU2009352678B2 (es)
CA (1) CA2774168C (es)
IN (1) IN2012DN02466A (es)
MX (1) MX2012003220A (es)
MY (1) MY174082A (es)
RU (1) RU2546005C2 (es)
WO (1) WO2011034551A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003220A (es) 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
WO2011132084A2 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
EP2718261B1 (en) * 2011-06-08 2016-02-24 Nitto Denko Corporation Compounds for targeting drug delivery and enhancing sirna activity
RU2635536C2 (ru) * 2012-03-01 2017-11-13 Новелион Терапьютикс Инк. Схемы лечения и способы улучшения зрительной функции при расстройствах зрения, связанных с дефицитом эндогенного ретиноида
US12029715B2 (en) 2015-05-08 2024-07-09 University Of Debrecen Precursor compounds for providing retinoids of the vitamin A5 pathway and uses thereof
CA2989490C (en) 2015-06-30 2023-02-14 Unilever Plc Composition containing vegetable oil, caramel and phenolic compounds
NZ748179A (en) * 2016-04-28 2025-08-29 Spark Therapeutics Inc Relative potency assay for viral vector encoding isomerohydrolases
HUE064808T2 (hu) 2016-11-17 2024-04-28 Univ Of Debrecen Prekurzor vegyületek az A5-vitamin útvonal retinoidjainak elõállítására és azok alkalmazása
EP4161502A4 (en) * 2020-06-09 2024-07-10 Eluminex Biosciences (Suzhou) Limited Methods of treating visual disorders using daily low dosing of a retinoid compound

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3196078A (en) 1962-01-30 1965-07-20 Ortho Pharma Corp Process for combating retinits pigmentosa
US3517067A (en) 1964-02-11 1970-06-23 Eastman Kodak Co Syntheses of quaternary phosphonium salts
DE2300107C2 (de) 1973-01-03 1982-03-11 Basf Ag, 6700 Ludwigshafen Vitamin A-Säureanilid-4-carbonsäureäthylester, Verfahren zu seiner Herstellung und diesen enthaltende Zubereitungen
CH590222A5 (es) 1973-08-21 1977-07-29 Hoffmann La Roche
US4022913A (en) * 1973-09-13 1977-05-10 Hoffmann-La Roche Inc. High potency vitamin A compositions
DE2456959A1 (de) 1974-12-03 1976-06-16 Basf Ag 4-(e)- und 4-(z)-7-methyl-9-(2,6,6trimethyl-1-cyclohexen-1-yl)-nona-2,4,6,8tetraencarbonsaeure, ihre derivate und diese enthaltende zubereitungen
US4532133A (en) * 1983-05-24 1985-07-30 Basf Wyandotte Corporation Low temperature stable, emulsifiable vitamin A concentrates
CA1282326C (en) 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
JPS61275266A (ja) 1985-05-28 1986-12-05 Taisho Pharmaceut Co Ltd レチノイド誘導体
CZ282548B6 (cs) 1992-01-22 1997-08-13 F. Hoffmann-La Roche Ag Farmaceutický přípravek
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
JPH06340525A (ja) 1993-06-02 1994-12-13 Lion Corp 安定な低眼刺激性ビタミンａ類可溶化点眼剤
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
RU2106843C1 (ru) 1994-06-29 1998-03-20 Красноярская государственная медицинская академия Способ лечения близорукости
JPH08198746A (ja) 1995-01-18 1996-08-06 Lion Corp 可溶化点眼剤
US5837728A (en) 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US5620970A (en) 1995-06-05 1997-04-15 Alcon Laboratories, Inc. Topical ophthalmic carbonic anhydrase inhibitor formulations
AU6390096A (en) * 1995-07-20 1997-02-18 Pharmacia & Upjohn Company Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
US5716627A (en) 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US5744148A (en) * 1996-09-20 1998-04-28 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
ZA989513B (en) 1997-10-21 1999-04-21 Alcon Lab Inc Compositions containing histamine H2 agonists and methods of use in treating dry eye
US6391924B1 (en) 1997-12-10 2002-05-21 Hampar Karageozian Taurine derivatives useable in the treatment of ophthalmic disorders
US6552009B2 (en) 1998-07-16 2003-04-22 Gentrix Llc Compositions and methods of treating abnormal cell proliferation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6372463B1 (en) 1999-05-06 2002-04-16 The President & Fellows Of Harvard College Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
US6300328B1 (en) 1999-08-06 2001-10-09 Alcon Universal Ltd. Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage
US20020028849A1 (en) 2000-04-18 2002-03-07 Godkin James D. Use of retinol in assisted-reproduction protocols
US6696069B2 (en) 2000-06-30 2004-02-24 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof
US20040077604A1 (en) * 2001-12-19 2004-04-22 Lenard Lichtenberger Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity
US20020142016A1 (en) * 2000-12-28 2002-10-03 Granger Stewart Paton Stable skin care product containing a retinoid and a retinoid booster system in a dual compartment package
EP1261623B1 (en) 2001-01-11 2009-11-04 Chebigen Inc. New retinol derivatives, the method of preparations and the uses thereof
CA2442670A1 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
ITMI20012366A1 (it) * 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
AU2002333114B2 (en) * 2001-11-30 2008-09-04 Qlt Inc. Hydrazonopyrazole derivatives and their use as therapeutics
EP1476147A4 (en) 2002-01-18 2005-03-09 Tatton Technologies Llc METHODS OF TREATING VIEW DISORDERS
US20030215413A1 (en) 2002-03-22 2003-11-20 L'oreal Compositions containing stabilized retinoid
US20040097587A1 (en) 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
US20030228277A1 (en) 2002-03-29 2003-12-11 Gehlsen Kurt R. Use of ROM production and release inhibitors to treat and prevent intraocular damage
JP3854524B2 (ja) 2002-04-01 2006-12-06 ピアス株式会社 油溶性成分安定化組成物及びその組成物を配合した化粧料、並びに油溶性成分の安定化方法
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP3326623A1 (en) 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
EP1510133A1 (en) 2003-09-01 2005-03-02 Belovo S.A., Egg Science & Technology Balanced oil composition
WO2005023094A2 (en) 2003-09-04 2005-03-17 The Uab Research Foundation Method and apparatus for the detection of impaired dark adaptation
US7706863B2 (en) 2004-01-21 2010-04-27 University Of Washington Methods for assessing a physiological state of a mammalian retina
AU2005215778B2 (en) 2004-02-17 2009-03-12 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CN1964706A (zh) 2004-03-17 2007-05-16 拉斯·M·拉森 通过抑制视觉周期预防视网膜病
LT2397133T (lt) * 2004-06-18 2018-01-10 University Of Washington Tinklainei skirti dariniai ir būdai, skirti naudoti regėjimo susirgimų gydymui
JP4855396B2 (ja) 2004-06-23 2012-01-18 リビジョン セラピューティクス， インコーポレイテッド レチナール誘導体で眼科的な状態を処置するための方法および組成物
US20060240098A1 (en) * 2004-07-14 2006-10-26 Aphios Corporation Formulations for hyperforin-enriched hypericum fractions
CA2575265A1 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat ophthalmic disorders
US20080275133A1 (en) 2004-09-30 2008-11-06 University Of Calfornia-San Francisco Local Administration of Retinoids to Treat Deficiencies in Dark Adaptation
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
AU2006311818B9 (en) 2005-11-07 2013-05-16 Murty Pharmaceuticals, Inc Improved delivery of tetrahydrocannabinol
US8202541B2 (en) 2006-02-07 2012-06-19 U.S. Nutraceuticals, LLC Dietary supplement composition for blood lipid health
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
JP5826459B2 (ja) 2007-01-15 2015-12-02 チョンシー ユー 非常に高い皮膚浸透率を有するレチノイド及びレチノイド様化合物の正に荷電した水溶性プロドラッグ
PT2187880E (pt) 2007-09-12 2014-03-25 Univ Columbia Composições e métodos para o tratamento da degenerescência macular
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
MX2012003220A (es) * 2009-09-15 2012-08-03 Quadra Logic Tech Inc Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
WO2011132084A2 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency

Also Published As

Publication number Publication date
JP5663025B2 (ja) 2015-02-04
CN102612375A (zh) 2012-07-25
CA2774168C (en) 2021-02-23
US20170007565A1 (en) 2017-01-12
US10736865B2 (en) 2020-08-11
AU2009352678B2 (en) 2015-05-21
RU2012114791A (ru) 2013-10-27
KR20120064707A (ko) 2012-06-19
US10130606B2 (en) 2018-11-20
KR101710505B1 (ko) 2017-02-27
CA2774168A1 (en) 2011-03-24
IN2012DN02466A (es) 2015-08-21
BR112012005905A2 (pt) 2020-02-18
HK1170158A1 (zh) 2013-02-22
WO2011034551A2 (en) 2011-03-24
CN102612375B (zh) 2016-01-27
AR076184A1 (es) 2011-05-26
JP2014185185A (ja) 2014-10-02
WO2011034551A3 (en) 2011-12-15
US20190183835A1 (en) 2019-06-20
RU2546005C2 (ru) 2015-04-10
MY174082A (en) 2020-03-09
AU2009352678A1 (en) 2012-04-05
US20120178806A1 (en) 2012-07-12
JP2013504617A (ja) 2013-02-07

Similar Documents

Publication Publication Date Title
MX2012003220A (es) Formulaciones farmaceuticas que comprenden 9-cis-retinil esteres en un vehiculo de lipido.
EP2493478B8 (en) Concentrated therapeutic phospholipid compositions
EP2663254A2 (en) Methods, systems and accessories useful for procedures relating to dental implants
GEP20186816B (en) Anty il-36r antybodies
WO2009154463A3 (en) Butyrate as a medicament to improve visceral perception in humans
MY205872A (en) Pharmaceutical compositions comprising omega-3 fatty acids
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MY188956A (en) Processes for producing lipids
EP2654695B8 (en) Enzymatic peracid generation for use in oral care products
IN2014CN02616A (es)
MX2014002159A (es) Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MY156518A (en) Borinic compositions
IN2012DN03807A (es)
EP2676172A4 (en) Direct generation semiconductor ircm laser system
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
EP2670339A1 (de) Dental-implantatsystem
AU2012345659A8 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
EP2785335B8 (en) Methods and pharmaceutical compositions for the treatment of darier disease
EP2672985A1 (en) Citrate free pharmaceutical compositions comprising anakinra
WO2012027601A9 (en) Methods targeting mir-33 micrornas for regulating lipid metabolism
PT2648666T (pt) Dispositivo de laser, especialmente para cirurgia oftalmológica a laser
MX2011011128A (es) Un producto lacteo bajo en colesterol para uso como un medicamento.

Legal Events

Date Code Title Description
FG Grant or registration